On the other hand, Abrahami et al. discovered that using dipeptidyl peptidase-4 inhibitors (DPP4i), a type of oral diabetic medication therapy in T2DM, can cause IBD, but another study presented contradictory findings, showing that DPP4i use in T2DM therapy could reduce the risk of IBD [38,39,40]. Here, DPP4 is linked to type 2 diabetes mellitus.